BRPI0910446A8 - rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna - Google Patents

rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna

Info

Publication number
BRPI0910446A8
BRPI0910446A8 BRPI0910446A BRPI0910446A BRPI0910446A8 BR PI0910446 A8 BRPI0910446 A8 BR PI0910446A8 BR PI0910446 A BRPI0910446 A BR PI0910446A BR PI0910446 A BRPI0910446 A BR PI0910446A BR PI0910446 A8 BRPI0910446 A8 BR PI0910446A8
Authority
BR
Brazil
Prior art keywords
double stranded
interference effect
rna
lipid modified
stranded lipid
Prior art date
Application number
BRPI0910446A
Other languages
English (en)
Inventor
Hidekazu Toyobuku
Hideki Ohba
Hirotake Hayashi
Takanori Kubo
Original Assignee
Nat Inst Of Advanced Ind Scien
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Of Advanced Ind Scien, Otsuka Pharma Co Ltd filed Critical Nat Inst Of Advanced Ind Scien
Publication of BRPI0910446A2 publication Critical patent/BRPI0910446A2/pt
Publication of BRPI0910446A8 publication Critical patent/BRPI0910446A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910446A 2008-03-31 2009-03-31 rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna BRPI0910446A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008094154 2008-03-31
PCT/JP2009/056638 WO2009123185A1 (ja) 2008-03-31 2009-03-31 Rna干渉効果が高い2本鎖脂質修飾rna

Publications (2)

Publication Number Publication Date
BRPI0910446A2 BRPI0910446A2 (pt) 2015-12-01
BRPI0910446A8 true BRPI0910446A8 (pt) 2016-07-26

Family

ID=41135556

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910446A BRPI0910446A8 (pt) 2008-03-31 2009-03-31 rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna

Country Status (11)

Country Link
US (1) US9040492B2 (pt)
EP (1) EP2264167B1 (pt)
JP (1) JP5906508B2 (pt)
KR (1) KR20100131509A (pt)
CN (1) CN101981185B (pt)
BR (1) BRPI0910446A8 (pt)
CA (1) CA2719963A1 (pt)
ES (1) ES2605618T3 (pt)
IL (1) IL208374A0 (pt)
RU (1) RU2501859C2 (pt)
WO (1) WO2009123185A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
CN109810977A (zh) * 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
CA2877985C (en) * 2012-07-10 2020-10-27 Baseclick Gmbh Anandamide-modified nucleic acid molecules
CN105899663B (zh) 2013-12-26 2019-07-26 学校法人东京医科大学 用于基因表达控制的人工模拟miRNA及其用途
SG10201913570XA (en) 2013-12-27 2020-03-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
SG11201705223XA (en) 2014-12-27 2017-07-28 Bonac Corp NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
WO2018181428A1 (ja) 2017-03-29 2018-10-04 塩野義製薬株式会社 核酸医薬及び多分岐脂質の複合体
EP3766972B1 (en) * 2018-03-14 2025-04-23 Institute of Science Tokyo Nucleic acid complex
WO2019217997A1 (en) * 2018-05-14 2019-11-21 Murdoch University Methods for treating vegf-related conditions
WO2021020412A1 (ja) 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
WO2025140190A1 (en) * 2023-12-25 2025-07-03 Microbio (Shanghai) Co., Ltd. Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
DE10302421A1 (de) * 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
WO2004090105A2 (en) 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20060014289A1 (en) * 2004-04-20 2006-01-19 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
WO2006113679A2 (en) * 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
WO2007030619A2 (en) 2005-09-08 2007-03-15 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007056861A1 (en) * 2005-11-18 2007-05-24 Protiva Biotherapeutics, Inc. Sirna silencing of influenza virus gene expression
US8906390B2 (en) 2006-03-24 2014-12-09 Gencia Corporation Synthetic lipid rafts and methods of use
JP2008167739A (ja) 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
JP4900943B2 (ja) 2006-12-25 2012-03-21 独立行政法人産業技術総合研究所 ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect

Also Published As

Publication number Publication date
BRPI0910446A2 (pt) 2015-12-01
ES2605618T3 (es) 2017-03-15
EP2264167A1 (en) 2010-12-22
JPWO2009123185A1 (ja) 2011-07-28
EP2264167B1 (en) 2016-10-12
IL208374A0 (en) 2010-12-30
RU2010144531A (ru) 2012-05-10
KR20100131509A (ko) 2010-12-15
WO2009123185A1 (ja) 2009-10-08
CN101981185B (zh) 2013-07-10
US20110034545A1 (en) 2011-02-10
JP5906508B2 (ja) 2016-04-20
CN101981185A (zh) 2011-02-23
RU2501859C2 (ru) 2013-12-20
US9040492B2 (en) 2015-05-26
CA2719963A1 (en) 2009-10-08
EP2264167A4 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
BRPI0910446A8 (pt) rna modificado por lipídeo de filamento duplo tendo alto efeito de interferência de rna
PT2350110T (pt) Novo glicosídeo de esteviol
EP2318919A4 (en) SPREAD MAP
BRPI0919426A2 (pt) métodos melhorado de exposição de rna
BRPI0909214A2 (pt) resolução de conflitos
EP2036018A4 (en) MIDDLEWARE ADVERTISING
EP2249690A4 (en) SEGMENTED INSTRUMENT WITH BRAKE POSSIBILITY
EP2150167A4 (en) SEMI-DISPOSABLE ENDOSCOPE
BRPI0914340A2 (pt) faixa de cabeça com coxim pivotal
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
EP2309333A4 (en) TONER
EP2063322A4 (en) Toner
BRPI0923090A2 (pt) método implementado por computador
EP2248460A4 (en) STEREOMICROSCOPE
BRPI0818079A2 (pt) composição de lipideo
EP2345935A4 (en) TONER
DE602007000609D1 (de) Toner
DE602007001937D1 (de) Optischer Tomograph
BRPI0924081A2 (pt) DERIVADOS DE 5- AMINO -2-(1-hIDROXI-ETIL)- TETRAHIDROPIRANO.
BRPI0910789A2 (pt) substratos tendo formulações com capacidade de transferência aperfeiçoada
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
BRPI0811261A2 (pt) Método de transmissão de informações
LU93092I2 (de) Alemtuzumab
FR2902879B1 (fr) Rheometre orthogonal
BRPI0911443A2 (pt) derivados de aminopiridina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]